entertainment -WSS

entertainment

author：focus 2025-10-01 14:40:23 - browse：41861

STAT@ASCO 2024 — Chris Boshoff, far right, speaking at a panel with, from left, Matthew Herper of STAT, Ken Keller, Levi Garraway, and Susan Galbraith. Megan Bearder Photography

CHICAGO — The ways clinicians can treat cancers effectively are expanding, partly because technologies today are making old ideas possible, said a panel of oncology industry leaders at STAT@ASCO, STAT’s event here at the annual American Society of Clinical Oncology meeting.

“We’re seeing this expansion in modalities. We have more types of modalities that have arrived or arriving that allow us to exploit targets we’ve known about more than ever before. It’s very exciting,” said Levi Garraway, the chief medical officer of Genentech, at the event. “Things we’ve known about for a long time can be drugged for the first time or in a new, different way.”

That’s led to a surge of new medicines ranging from small molecules to cell therapies, with the potential uses of these treatments expanding into earlier lines of therapy and more cancer types each year. One example the panel singled out is the drug Enhertu, which recently received a tumor-agnostic approval from the Food and Drug Administration.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Amylyx ALS drug fails large clinical trial

knowledge

WSS

Change Healthcare payments predicted restored March 15

New clues to why women have higher risk of autoimmune disorders

Novo Nordisk obesity pill bests Wegovy in early trial

Amylyx ALS drug failure raises questions and concerns

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

Zyn nicotine pouches become unlikely player in latest culture war

focus

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

entertainment

How to save PrEP access — and even expand it

Philips to halt sales of sleep apnea machines in U.S.

Hepatitis C has a cure — but many Americans still lack access to it

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

Sports medicine is finally prioritizing gender equality

First medicine developed to treat MASH expected to be approved soon

Activists slam private health insurers over coverage restrictions

Medicare Advantage insurers face 0.2% cut to 2025 payments

United colonoscopy coverage change 'may cost lives,' doctors say

The drug industry has found itself all alone in Washington

hotspot

RSV shot was 90% effective at preventing hospitalizations in kids

Change Healthcare payments predicted restored March 15

UnitedHealth quietly bought dozens of outpatient centers

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

Medicare drug price negotiation legal challenge met with skepticism

Precocious puberty in girls comes with mental health risks

hotspot

focus

knowledge

leisure time